Ravidasvir: equitable access through an alternative drug development pathway

Cheong, Wing Loong; Piédagnel, Jean-Michel; Khor, Swee Kheng

doi:10.1016/s2214-109x(21)00357-0

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malaysia is among the first nation in the world 16 to approve the use of ravidasvir, a new pan-genotypic, second-generation inhibitor of hepatitis C virus of the NS5A protein. 17 It is cost-effective alternative therapy for chronic hepatitis C infection. It is hoped that the new treatment can provide better treatment accessibility among opioid dependents who are hepatitis C positive.…”

Section: Resultsmentioning

confidence: 99%

Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study

Khalid

Ooi

Rashid

et al. 2022

East Asian Arch Psychiatry

View full text Add to dashboard Cite

Objectives: To determine the prevalence of continued illicit drug use among people enrolled in methadone maintenance treatment (MMT), the association between hepatitis C status and methadone dosage, and the predictors for illicit drug abstinence during MMT. Methods: Clinical records of active opioid dependents who underwent MMT between 1 January 2007 and 31 March 2021 in Hospital Tuanku Fauziah, Perlis, Malaysia were retrospectively reviewed. Data collected included baseline demographics, history of illicit drug use, temporal trend in methadone dosage modulation, and co-use of illicit drugs during the MMT. Results: A total of 87 patients (mean age, 43.9 ± 8.33 years) were included. Their mean duration of involvement in MMT was 7.8 ± 3.69 years. The most commonly used drug was heroin (88.5%), followed by kratom (51.7%). Between 2019 and 2021, 61 (70.1%) patients had ceased abusing opioid, but 51 (58.6%) patients continued using any of the illicit drugs. Methamphetamine and amphetamine co-use was most common (n = 12, 37.5%). Hepatitis C status was not associated with the current methadone dose (U = 539.5, p = 0.186) or the highest dose required (t = -0.291, df = 74, p = 0.772). No predictor for illicit drug abstinence during MMT was identified. Methadone dose positively correlated with frequency of defaulting treatments (r = 0.22, p = 0.042). Conclusion: Among our patients, MMT for opioid dependents cannot sufficiently curb illicit drug use, and there is a shift toward stimulants abuse.

show abstract

Section: Resultsmentioning

confidence: 99%

Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study

Khalid

Ooi

Rashid

et al. 2022

East Asian Arch Psychiatry

View full text Add to dashboard Cite

show abstract

Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials

Parikh

Mahalakshmi³

et al. 2023

Arabian Journal of Chemistry

View full text Add to dashboard Cite

Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C

Vieira,

Slovenski,

Large

et al. 2024

TropicalMed

View full text Add to dashboard Cite

Alternative innovation models have emerged to address failures of the traditional pharmaceutical system, particularly for diseases where market incentives do not attract sufficient research and development efforts. However, the feasibility of such models for diseases with significant markets is not well-established. This article analyses the development of a novel drug (ravidasvir) for the treatment of hepatitis C, a highly profitable market. Data from qualitative research methods, including literature reviews and semi-structured interviews, was analyzed using a novel conceptual framework focusing on actors, resources, organizational practices, and outcomes. Dissimilar to other projects, ravidasvir did not involve any major pharmaceutical companies. Rather, it leveraged the capacities of actors less traditionally involved in the development of novel medicines by constructing a collaborative network of private and public partners from low- and middle-income countries with a shared goal. The collaboration was successful in developing a highly effective, easy-to-use, and affordable medicine and contributed significantly to capacity-strengthening. However, the case also highlighted that strategic behavior by competing for-profit firms could pose significant challenges and that changing external conditions reduced the potential public health impact of the drug. Lessons from ravidasvir can inform future efforts to develop alternative innovation models for therapeutic areas with significant commercial interest.

show abstract

Ravidasvir: equitable access through an alternative drug development pathway

Cited by 3 publications

References 5 publications

Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study

Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study

Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials

Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C

Contact Info

Product

Resources

About